EUCTR2009-015859-24-SE进行中（未招募）不适用
/A - Effect of zonisamide-induced weight reduction compared to nCPAP in patients with sleep apnoea
The Sahlgrenska Academy, University of Gothenburg0 个研究点目标入组 90 人开始时间: 2009年10月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of informed consent prior to any study specific procedures
- •2.Males/females 18 to 75 years
- •3.An Apnea-Hypopnea Index (AHI)>15 and an Epworth Sleepiness Scale score (ESS)>6
- •4.Body mass index (BMI) between >27 and <35 kg/m2 (mild to moderate)
- •5.Clinically normal physical findings and laboratory values, as judged by the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Hypersensitivity to sulfonamides or zonisamide.
- •2.History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
- •3.Subjects with a seizure disorder
- •4.Clinically significant renal (serum creatinine >2.0 mg/dL or >130 ?mol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT >2 times the upper limit of normal).
- •5.Subjects who have taken any weight loss medications (prescription or over-the-counter) within one month prior to Enrollment
- •6.Subjects with occupations designated as high risk or safety sensitive including patients who have to handle complex machinery or are professional drivers where there may be an increased risk for work or traffic accidents.
- •7.Unstable angina pectoris, unstable hypertension (diastolic blood pressure above 100 on treatment for more than 3 months), diabetes (fasting plasma glucose above 7 mmoles/l)
- •8.Uncontrolled congestive heart failure
- •9.Myocardial infarction or coronary vessel intervention within the previous 6 months period
- •10.Subjects with uncontrolled hypertension (defined as a diastolic blood pressure ?100 mmHg and/or a systolic blood pressure =180 mmHg with or without medication). Hypertensive subjects on medications must have been on the same dose of the same antihypertensive medication for at least two months prior to Enrollment.
- •11.Previously diagnosed or treated clinically significant cardiac arrhythmia
- •12.Clinically significant chronic pulmonary or gastrointestinal disease
- •13.Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease
- •14.Pregnancy or lactation. Women of childbearing potential should use effective birth control prior to and during the study
- •15.Suspected or confirmed poor compliance
- •16.Alcohol or drug abuse during the last year
- •17.Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.
- •18.Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgement.
- •19.Participation in another clinical study during the last 6 months
- •20.Inability to understand and complete the questionnaires
研究者
相似试验
已完成
不适用
Zonisamide for Weight Reduction in Obese AdultsObesityNCT00275834Duke University225
已完成
不适用
on-inferiority study of zonisamide versus levodopa preparations in DLB parkinsonismParkinsonism with Dementia with Lewy bodiesJPRN-jRCTs051200054Ikeda Manabu130
已完成
4 期
Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled TrialObesityNCT00203450Tuscaloosa Research & Education Advancement Corporation20
已完成
不适用
Effect of zonisamide on psychotropic drug induced weight gaiPsychotropic drug induced weight gainJPRN-UMIN000037437Hokkaido Prefectural Midorigaoka Hospital10
终止
2 期
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic SubjectsSchizophreniform DisorderSchizophreniaSchizoaffective DisorderNCT00734435Orexigen Therapeutics, Inc26